Upadacitinib

Evidence Level: L5

Predicted Indications: 2

Upadacitinib

Pharmacist Assessment Report

Upadacitinib: Colobomatous microphthalmia-rhizomelic dysplasia syndrome

One-Sentence Summary

Upadacitinib is an oral JAK inhibitor, originally used to treat rheumatoid arthritis. The TxGNN model predicts it may be effective for colobomatous microphthalmia-rhizomelic dysplasia syndrome, a rare developmental disorder, but there are currently 0 clinical trials and 0 publications supporting this prediction. It is a model-based signal only.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Colobomatous microphthalmia-rhizomelic dysplasia syndrome
TxGNN Prediction Score	0.9961
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, upadacitinib belongs to the Janus kinase (JAK) inhibitor class (JAK1-preferential), and its efficacy in rheumatoid arthritis is established through modulation of inflammatory cytokine signalling.

The predicted indication is a rare congenital developmental dysplasia. No plausible link between JAK-STAT signalling and this condition is evident from the data compiled for this report. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It should be treated as a hypothesis-generating signal rather than evidence of benefit.

Other high-ranking predictions show the same pattern. Only the myeloma entries have even a theoretical rationale, via IL-6/JAK/STAT3 signalling in plasma cell survival, and none has supporting clinical data.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 11979L	Rinvoq	Tablet 15 mg (oral)	Not available in the data compiled for this report

Safety Considerations

Drug Interactions (100 interactions identified; main examples shown):

Major: systemic and inhaled corticosteroids (hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, triamcinolone, budesonide, beclomethasone), clarithromycin, cobicistat, deferiprone, iobenguane (I-131)
Moderate: aprepitant, cimetidine, miconazole, deferasirox
Minor: zinc salts (sulfate, acetate, gluconate)

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications. Class-level concerns for JAK inhibitors include serious infection, malignancy and venous thromboembolism.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests solely on a model score, with no clinical trials, no literature and no identifiable mechanistic link to JAK inhibition. Evidence is at the lowest level (L5).

To proceed, the following is needed:

Detailed mechanism of action data (MOA) and a biologically plausible link to the predicted disease
Systematic literature and trial registry searches (including ANZCTR) for the predicted indication
TGA Product Information warnings and contraindications for safety screening
Review of the approved indication text for the ARTG entry
If a repurposing direction is pursued, consider the myeloma-related predictions only as hypotheses, with a dedicated assessment of infection and malignancy risk
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.